Dr. Reddy's Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's has received a Post-Application Action Letter (PAAL) from the USFDA in connection with its biologics manufacturing facility in Bachupally, Hyderabad. This follows a Pre-Approval Inspection (PAI) conducted earlier, which the company had disclosed on September 13, 2025. The PAAL comes after Dr. Reddy's submitted its response to the USFDA's earlier observations. The company has stated it will work closely with the USFDA and is committed to addressing the queries raised. A PAAL generally indicates that the regulator has additional questions or concerns before granting product approval.
This is a regulatory setback that could delay approvals for biologic products from the Bachupally facility, potentially affecting future revenue from that plant. However, the company has not reported any supply disruption or warning letter, and the issue appears to be addressable through further engagement with the USFDA.